Monoclonal Antibodies Enhancing Anti-Cancer Immunity

Steps:

• Review each description: 1 activates immune response via cell surface binding; 2 removes T-cell suppression; 3 interrupts signaling that could hinder immune targeting; 4 suppresses overall immunity.
• Match to cancer therapy: Effective mAbs either trigger immune attack on tumors (1), unleash T-cells by blocking checkpoints (2), or block pro-tumor signaling pathways (3).
• Eliminate 4: Binding immune-inhibiting molecules would weaken anti-cancer defenses, unsuitable for treatment.
• Select combination: 1, 2, and 3 align with standard cancer mAb strategies like rituximab (1), pembrolizumab (2), and trastuzumab (3).

Why B is correct:

• B includes 1, 2, and 3, which directly support tumor targeting and immune activation per oncology guidelines on mAb mechanisms.

Why the others are wrong:

• A includes 4, which promotes immune suppression counterproductive to cancer therapy.
• C omits 2, excluding key checkpoint inhibitors essential for immunotherapy.
• D pairs 2 with 4, combining T-cell enhancement with immune inhibition, yielding no net anti-cancer benefit.

Final answer: B